sunitinib

1. Introduction Sunitinib mesylate (Sutent®) is a multikinase inhibitor approved by the FDA and EMA for several advanced malignancies. It is classified as a targeted therapy, specifically a tyrosine kinase inhibitor (TKI), with broad activity against receptor tyrosine kinases (RTKs) implicated in tumor growth, angiogenesis, and metastasis. Its use requires careful clinical oversight due to…